Author

E. Wayne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. E. D. Van Swearingen· 1 shared A. Folch· 1 shared A. Locke· 1 shared A. V. Kabanov· 1 shared C. Ahls· 1 shared C. Stiles· 1 shared C. V. Pecot· 1 shared D. Hwang· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. E. D. Van Swearingen

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Functional evaluation of microdissected tumor 'cuboids': a microscale ex vivo cancer model that retains a complex tumor microenvironment

L. F. Horowitz, R. A. Rodriguez-Mias, M. Chang, S. Zhu, Y. Tang, A. Locke, N. R. Gottshall, I. Stepanov, C. Stiles, M. Yeung, T. N. Nguyen, E. J. Lockhart, C. Ahls, E. Wayne, W. Wei, , A. Folch

The paper develops a microscale ex vivo cancer model using tumor cuboids that retain a complex tumor microenvironment, enabling drug and immunotherapy testing.

bioRxiv · Mar 22, 2024 · PreprintCancer Biology

High Capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of Lung Adenocarcinoma

N. Vinod, D. Hwang, S. H. Azam, A. E. D. Van Swearingen, E. Wayne, S. C. Fussell, M. Sokolsky-Papkov, C. V. Pecot, A. V. Kabanov

This study shows that a novel nanomicellar formulation of Resiquimod extends survival in a metastatic lung adenocarcinoma model more effectively than chemotherapy and anti-PD1 therapy.

bioRxiv · Dec 12, 2019Pharmacology & Toxicology